Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04642547 Completed - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Start date: December 2, 2020
Phase: N/A
Study type: Interventional

This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study will help find out if lenvatinib and gefitinib is a safe and useful combination for treating patients with lenvatinib resistant hepatocellular carcinoma.

NCT ID: NCT04641637 Completed - Clinical trials for Hepatocellular Carcinoma

Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC

Start date: June 30, 2022
Phase: N/A
Study type: Interventional

It is postulated that all arterial tumor feeders supplying a HCC tumor are interconnected with each other through the tumor sinusoid, such that when one of the feeders is catheterized for delivery of a liquid embolic agent, the whole tumor sinusoid will be embolized, if the arterial blood flow in all the other feeders are stopped temporarily to create a negative pressure gradient.

NCT ID: NCT04627012 Completed - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Start date: January 1, 2018
Phase:
Study type: Observational

For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC. This study will create a database that will provide clinical parameters and outcomes of patients undergoing Lenvatinib and anti-PD1 antibody as part of their standard of care in hopes of answering key clinical questions.

NCT ID: NCT04618367 Completed - Clinical trials for Carcinoma, Hepatocellular

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

NCT ID: NCT04599790 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).

NCT ID: NCT04599777 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).

NCT ID: NCT04576572 Completed - Clinical trials for Hepatocellular Carcinoma

Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma

Start date: June 15, 2020
Phase:
Study type: Observational

Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis. However, liver transplantation is not offered to every HCC patient, since advanced stage HCC patients are lost with tumor recurrence early after liver transplantation. The Milan criteria, which are accepted worldwide, are the patient selection criteria that we have to follow in cadaver-to-liver transplantation for HCC in our country. However, as the Milan criteria are very strict criteria, it pushes patients out of liver transplantation who exceed the Milan criteria but who can benefit from liver transplantation. Liver transplantation centers all over the world have declared their own criteria under the expanded Milan criteria. In our country, Malatya Criteria have been defined by İnönü University on this subject, and our studies on this subject still continue. When we scan the original articles of all these defined criteria, incomplete data are formed and therefore the strength of the criteria cannot be clearly revealed. For this reason, we aimed to analyze the results of our center and present information about the power of the criteria to the literature.

NCT ID: NCT04569799 Completed - Clinical trials for Hepatocellular Carcinoma

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE

TACE
Start date: October 14, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC) after receiving TACE treatment

NCT ID: NCT04568330 Completed - Clinical trials for Hepatocellular Carcinoma

Prevention of Hand-foot Skin Reaction

Start date: March 21, 2014
Phase: N/A
Study type: Interventional

Sorafenib-induced hand-foot skin reaction (HFSR) is a dose-dependent side effect in patients with advance hepatocellular carcinoma (HCC). The appropriate prophylactic dose of urea-based cream and comparison of its effectiveness with other creams remain unclear. The aim of this study was re-validating the prophylactic HFSR incidence density and cutaneous wetness of 10% urea-based cream on sorafenib-induced HFSR in patients with advanced HCC.

NCT ID: NCT04562428 Completed - Clinical trials for Hepatocellular Carcinoma

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

Start date: November 20, 2020
Phase: Phase 4
Study type: Interventional

The purpose of the study was search the safety and efficacy of the of Xiang Sha Liu Jun Zi Decoction (XSLJZ) in advanced hepatocellular carcinoma patients with multiple protein kinase inhibitor therapy. Evaluate the treatment effect on the symptoms of appetite and quality of life in advanced hepatocellular carcinoma patients